Report Description Table of Contents Point of Care Diagnostics Market Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted, Go-to-Market (GTM) Strategy, Government Regulations, Reimbursements, FDA Approvals, Supply Chain Analysis, Startup Ecosystem & Product Rating, AI Adoption, etc. The global point of care diagnostics market will witness a robust CAGR of 11.78%, valued at $33.12 billion in 2021, expected to appreciate and reach $90.25 billion by 2030, confirms Strategic Market Research. Point of care (POC) diagnostic includes execution of a diagnostic test outside a laboratory that delivers a quick and reliable result, assisting in the identification and management of acute infections and chronic diseases. The growing global popularity of fast testing kits will promote revenue creation from point-of-care diagnostics in the future. It must be noted that the POC diagnostics products can be split in two broad segments which are infectious and non-infectious PoC testing. The non-infectious PoC testing takes a share of 40% while the infectious PoC testing accounts for a larger, 60% of the market. Moreover, the Covid 19 pandemic has led to an even higher demand for PoC testing kits for this infectious pandemic. With revenue of USD 8,624.1 million, the glucose monitoring segment held a significant position in the overall point of care diagnostic market in 2021. It is due to the increasing incidence of diabetes and the growing sales of diabetes rapid diagnostic kits worldwide. Furthermore, the infectious disease testing segment is likely to grow at the fastest CAGR due to the increasing incidence of infectious diseases worldwide. In 2021, the OTC testing segment ruled the overall market with the largest revenue share of 58.4% in terms of prescription and will grow at a rapid rate. This segment has the largest share because they are easy to operate and cost-effective. This test does not require skilled professionals and can be performed at home. The hospital sector ruled the overall market with a significant revenue share in 2021, and by 2030 it is estimated to reach USD 25.3 billion on the basis of end-user. The largest share of this segment is due to the increasing frequency of various diseases such as chronic disorders, increased hospitalization rate, rapid investment by both private and public sectors to develop well established healthcare infrastructure, and rising usage of advanced equipment. Additionally, the urgent care and clinic segment is predicted to develop at a quicker rate during the forecast period. North America led the overall point of care diagnostic market in 2021 and generated a revenue of USD 14.48 billion, and by 2030 it will be around USD 32.5 billion. Because of rising infectious disease incidence and the rising cases of chronic diseases among the population, North America rules the worldwide point of care diagnostics market. Due to the increased manufacturing of innovative products, Europe is predicted to hold the second-highest position in the world market at the time of the projected period. Furthermore, increased government R&D spending is likely to support the regional market growth. Point-of-Care Diagnostics (POC) is an integral part of clinical diagnostics that helps assess chronic diseases and acute infections. In the United States, 7 out of 10 people die yearly from chronic diseases. Chronic diseases cause more than 38 million deaths each year around the world, with cardiovascular diseases resulting in the primary cause of fatalities (approximately 17.5 million people each year), followed by Cancer (8.2 million), diseases related to the respiratory systems (4 million), and diabetes (1.5 million). Acute infections involve influenza, pneumonia, respiratory tract infection, etc. Acute respiratory infection (ARI) is one of the major causes of fatalities in children. It is estimated that approximately every year, around (11 to 22) % of deaths among children under five years and 3% of deaths among adults between (15 to 49) years of age occur globally due to ARI. The above statistics are going to have a positive impact on the growth rate of the point of care diagnostics market during the projected period of 2021-2030. Point of care testing provides ample opportunities for the community pharmacies to increase their revenue by expanding patient care services worldwide. The point of care testing device is an instrument implemented for acquiring clinical information about patients worldwide. The POCT devices contribute nearly (7-8) % of the entire medical devices market. Moreover, these devices created a significant impact on the whole microbiological culture. The applications of POCTs for microbiology can be used as a surveillance tool to identify pathogens like the influenza virus and Zika virus. The Point of Care Faecal Immunochemical Testing (POCFIT) is widely used to detect the hemoglobin content in the feces and is also used as a screening tool to detect Colorectal Cancer (CRC). Faecal Matter occurs due to the absorption of insufficient fluid by the colon. COVID-19 Impact Analysis The sudden COVID-19 outbreak had a positive impact on the market. It has increased the demand for diagnostic kits to rapidly detect chronic diseases and acute infections. With the rapid increase in the need for prompt diagnostic results due to the COVID-19 pandemic, the demand for POC drastically rose worldwide. Moreover, the rising prevalence of COVID-19 cases all across the globe has compelled governments to invest more in patient management, which has immensely boosted the demand for rapid antigen tests. Such a rapidly detecting tool is very much crucial for providing accurate treatment options to patients. The ELISA test was also introduced to check whether an individual has antibodies in their blood against the SARS-CoV-2 virus. Furthermore, point-of-care diagnostics tests are conducted to detect current or past SARS-CoV-2 virus infections adequately. Point of Care Diagnostics Market Drivers Analysis An uprise in the prevalence of infectious diseases worldwide is one of the significant causes that is fuelling the overall market growth. According to WHO, more than 17 million people worldwide die each year due to infectious diseases, thereby leading to the robust growth of the POC Diagnostics Market. Lab-on-a-chip technology is also one of the pivotal drivers of POC testing that enables the different bioassays like PCR and ELISA tests to be conducted at the POC centers, driving the market at a good pace. Usage of saliva as a liquid biopsy, a rise in the need for POC testing in clinical microbiology, and an increase in investments by the leading market players in point care diagnostics are some of the vital causes driving the overall growth rate of the market. Also, the rising prevalence of several POC testing processes like Neuropsychological tests, urine analysis, pregnancy tests, testing for Chlamydia, cholesterol levels, international normalized ratio tests, Haemoglobin A1c tests, blood alcohol content, cardiac biomarkers, D-dimer, ionized calcium levels, arterial blood test gas analysis, electrolyte test, lactate blood test, point of care coagulation testing, Multiplexed point-of-care testing, etc. are propelling the overall market growth to a great extent. Market Restraints Analysis The implication of stringent regulatory policies by the FDA is a significant barrier that can restrain the overall market growth. Market Report Covering Opportunities and Latest Technology Trends Decentralization of healthcare centers all across the globe has highly increased the efficacy rate of the market and is likely to make substantial growth in the future. US healthcare systems have already implemented this technique, while many European countries are widely focusing on decentralizing their healthcare systems. Also, the usage of IVD point-of-care test devices is increasing rapidly. Therefore, it is highly estimated to improve the future UK Global Point-of-Care Diagnostics Market outlook. Point of Care Diagnostics Market Analysis Of Different Segments Covered in the Report Based on Product Glucose Monitoring Products Infectious Disease Testing Products Coagulation Monitoring Products Fecal Occult Testing Products Cardiometabolic Monitoring Products Pregnancy & Fertility Testing Products Cholesterol Testing Products Cancer Marker Testing Products Urinalysis Testing Products Haematology Testing Products Drugs-of-abuse Testing Products Other POC Products Based On Mode of Purchase OTC Testing Products Prescription-based Testing Products Based On Platform Lateral Flow Assays Immunoassays Microfluidics Molecular Diagnostics Dipsticks Based On End-User Hospitals and Critical Care Centers Home Care Outpatient and Ambulatory Care Facilities Others Regional Coverage Analysis North America US Canada Mexico Rest of North America Europe Russia Switzerland U.K Finland Spain France Turkey Netherlands Germany Belgium Italy Rest of Europe Asia Pacific India China Malaysia South Korea Australia Thailand Japan Indonesia New Zealand Philippines Singapore Rest of Asia-Pacific LAMEA Uruguay Brazil Saudi Arabia Argentina Rest of LAMEA Product Analysis & Insights Glucose Monitoring Products dominated the market in 2020 with a CAGR of 7.73% and a market share of USD 12.73 billion due to the increase in demand for home glucose testing, a continuous rise in the number of patients, and the adoption of highly upgraded technologies among the researchers worldwide. Mode of Purchase Analysis & Insights OTC Testing Products has the largest market share with an overall CAGR of 11.63%. The demand for early detection of diseases and growing awareness of the usage of POC products are driving the growth of this segment significantly. Platform Analysis & Insights Lateral Flow Assays dominated the market comprehensively in 2020, with a CAGR of 4.93% and an overall share of 8.273 billion due to the increase in LFA-based POC devices and a rise in awareness of POC testing advantages. End-User Analysis & Insights Hospitals and Critical Care Centres accounted for the largest market share due to the rise in demand for cost-effective and highly efficient POC diagnostics products, rising prevalence of long-term care, and frequent monitoring of chronic illness and acute infections. According to the AHA (American Hospital Association), at present, there are a total of 6090 hospitals in the United States out of which there are 2946 Nongovernment Not-for-Profit Community Hospitals, 962 Local and State Government Community Hospitals, 1233 Investor-Owned (For-Profit) Community Hospitals, 625 Non-Federal Psychiatric Hospitals, 208 Federal Government Hospitals, and 116 other types of hospitals. Point of Care Diagnostics Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 33.12 billion The revenue forecast in 2030 USD 90.25 billion Growth rate CAGR of approximately 11.78% The base year for estimation 2021 Historical data 2015 – 2019 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Mode of Purchase, By Platform, By End-User, By Region By Product Glucose Monitoring Products, Infectious Disease Testing Products, Coagulation Monitoring Products, Fecal Occult Testing Products, Cardiometabolic Monitoring Products, Pregnancy & Fertility Testing Products, Cholesterol Testing Products, Cancer Marker Testing Products, Urinalysis Testing Products, Haematology Testing Products, Drugs-of-abuse Testing Products, Other POC Products By Mode of Purchase Hospitals and Critical Care Centers, Home Care, Outpatient and Ambulatory Care Facilities, Others By Platform Lateral Flow Assays, Immunoassays, Microfluidics, Molecular Diagnostics, Dipsticks By End-User Oil-free, Oil-filled By Region North America, Europe, Asia-Pacific, LAMEA. Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Chembio Diagnostics, Quidel Diagnostics, EKF Diagnostics, Trinity Biotech, Fluxergy Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Regional Analysis: North America dominated the POC diagnostics market with an overall CAGR of 9.83% because of highly favorable government policies, high awareness of self-testing, etc. In 2020, the US point of care diagnostics market size accounted for up to USD 5.83 billion. The European Point of Care Diagnostic Market is estimated to be the second-largest market after North America. UK, France, and Germany are the three most dominant countries in the European POC diagnostics market. On the other hand, Asia Pacific is the fastest-growing region of the market. The Market in India resulted in high growth potential for the organizations involved in the development and distribution of point of care devices. Moreover, the market in the Asia Pacific region is growing comprehensively with a steady CAGR and is expected to reach up to USD 7.98 billion by 2028. Global Point of Care Diagnostics Market Competitive Landscape Analysis The competitive landscape is the best tool for identifying the key competitors existing in the market environment worldwide. The comparison is made based on the total cost involved in R&D, global presence, market initiatives, market capability, company overview and financials, revenue generation, production facilities and sites, production capacity, organization flaws, strengths, etc. Roche Diagnostics Siemens Healthineers Abbott Laboratories Danaher Corporation Becton Dickinson and Company Chembio Diagnostics Quidel Diagnostics EKF Diagnostics Trinity Biotech Fluxergy Recent Developments: - On Oct 2021, the United States FDA approved Roche’s Tecentriqwas introduced as adjuvant therapy for people suffering from early stages of lung cancer. Tecentriq is the only existing cancer immunotherapy that is available for adjuvant treatment of NSCLC. On Mar 2020, Abbott launched the Molecular Point-Of-Care test for accurately detecting the Novel Coronavirus that works within five minutes. This test will continue to run on Abbot’s ID NOW platform, thus providing quick results in several healthcare facilities such as urgent care clinics, physician’s offices, and hospital emergency departments. The Critical POC Devices that Market Leaders Develop Name of the product Function Key Players DCA Vantage Analyzer Chronic disease management Siemens Healthineers AFINION 2 Near Patient Testing at Point of Care Abbott Laboratories DPP SARS-CoV-2 Antigen Detection of nucleocapsid protein antigen to SARS-CoV-2 Chembio Diagnostics Frequently Asked Question About This Report Who are the major players in the global market? The key players in the global market are Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Chembio Diagnostics, QuidelDiagnostics, EKF Diagnostics, Trinity Biotech, and Fluxergy. How big is the point of care diagnostics market? The global point of care diagnostics market size was $33.12 Bn in 2021 and is predicted to reach $90.25 Bn by 2030, with a CAGR of 11.78%. What are the factors driving the market? Increase in prevalence of infectious diseases, technological advancements in the POC devices, and increase in investments by the leading market players are the factors that are driving the market. Which end-user segment in the POC diagnostics market held the largest revenue share in 2021? Among the end-user segment, ‘Hospitals and Critical Care Centres’ in the POC diagnostics market held the largest revenue share in 2021. What is the point of care diagnostics market growth? The global point of care diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 11.78% from 2021 to 2030 to reach USD 90.25 billion by 2030. Which market segment accounted for the largest market share based on the product? Based on product, the ‘Glucose Monitoring Products’ segment accounted for the largest market share. Sources https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498661/ https://www.who.int/news/item/01-01-1996-infectious-diseases-kill-over-17-million-people-a-year-who-warns-of-global-crisis https://www.totalvoicetech.com/number-of-hospitals-in-the-us/ Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusion and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Market Segmentation 1.3.2 Geographic Scope Figure 02: Market Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.2.1.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at Market size by bottom-up analysis Figure 03: Market: Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: Market: Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 Market: Post-Covid-19 Figure 06: Impact of Covid-19 on Market 3.1.1 Actual Scenario Figure 07: Realistic Scenario: Market, 2020–2030 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: Market, 2020–2030 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: Market, 2020–2030(USD Million) 3.1.4 Market Summary Figure 10: Glucose Monitoring Products to Witness Highest CAGR in Market, By Product, During Forecast Period Figure 11: Hospitals and Critical Care Centres to Witness Higher CAGR in Market for End-User Segment during Forecast Period Figure 12: OTC Testing Products to Witness Higher CAGR in Market for Mode of Purchase Segment during Forecast Period Figure 13: Lateral Flow Assays to Witness Higher CAGR in Market for Platform Segment during Forecast Period Figure 14: North America to Account for Largest Share of Global Market In 2020 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 15: Market Segmentation Chapter 5. Industry Outlook 5.1 Market Snapshot 5.2 Global Point of Care Diagnostics Market 5.2.1 Global Market, 2020 – 2030 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Market, by region, 2021-2030 (USD Million) 5.4 Product Segment Analysis 5.4.1 Market, by Product, 2021-2030 (USD Million) 5.5 End-User Segment Analysis 5.5.1 Market, By End-User, 2021-2030 (USD Million) 5.6 Value Chain Analysis 5.7 Market Variable Analysis 5.7.1 Market Drivers Analysis 5.7.2 Market Restraints Analysis 5.8 Business Environment Analysis Tool 5.8.1 Market PEST analysis 5.8.2 Market Porter’s analysis 5.9 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 16 Market: Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 17 Market Drivers and Their Impact 6.2.2 Restraints Figure 18 Market Restraints and Their Impact 6.2.3 Opportunities Figure 19 Market Opportunities and Their Impact 6.2.4 Challenges Figure 20 Market Challenges and Their Impact 6.3 Impact of Covid-19 on Market 6.4 Value Chain Analysis Figure 21 Value Chain Analysis: Market 6.5 Ecosystem Figure 22 Market: Ecosystem Table 3 Market: Ecosystem Figure 23 Revenue Shift in Market 6.6 Patent Analysis Table 4 Number of Patents Registered in Market in USA in Last 9 Years Figure 24 Top 10 Companies with Highest No. of Patents in Last 9 Years Figure 25 No of Patents Granted Per Year, 2019–2020 Table 5 List of Global Patents in Market 6.7 Trade Analysis 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 6: Market: Porter’s Five Forces Analysis, 2020 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Mode of Purchase Analysis 6.11.1 Trends in Mode of Purchase (2014-2020) 6.11.2 Trends in Mode of Purchase (2021-2030) Table 7 Key Regulations: Market 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Country) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 8: Key Players Market share Figure 26: Key players Market share of companies 7.2 Manufacturers Manufacturing Sites, Area Served, Product 7.3 Market Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global Market: Product Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2021-2030) Table 9 Market, By Product, 2021–2030 (USD Million) Figure 27 Market, By Product Figure 28 Glucose Monitoring Products Segment to Register Highest CAGR in Market during Forecast Period 8.3 Glucose Monitoring Products 8.3.1 Glucose Monitoring Products Market, 2021-2030 (USD Million) Figure 29: Glucose Monitoring Products Market, 2021-2030 (USD Million) 8.4 Infectious Disease Testing Products 8.4.1 Infectious Disease Testing Products Market, 2021-2030 (USD Million) Figure 30: Infectious Disease Testing Products Market, 2021-2030 (USD Million) 8.5 Coagulation Monitoring Products 8.5.1 Coagulation Monitoring Products Market, 2021-2030 (USD Million) Figure 31: Coagulation Monitoring Products Market, 2021-2030 (USD Million) 8.6 Fecal Occult Testing Products 8.6.1 Fecal Occult Testing Products Market, 2021-2030 (USD Million) Figure 32: Fecal Occult Testing Products Market, 2021-2030 (USD Million) 8.7 Cardiometabolic Monitoring Products 8.7.1 Cardiometabolic Monitoring Products Market, 2021-2030 (USD Million) Figure 33: Cardiometabolic Monitoring Products Market, 2021-2030 (USD Million) 8.8 Pregnancy & Fertility Testing Products 8.8.1 Pregnancy & Fertility Testing Products Market, 2021-2030 (USD Million) Figure 34: Pregnancy & Fertility Testing Products Market, 2021-2030 (USD Million) 8.9 Cholesterol Testing Products 8.9.1 Cholesterol Testing Products Market, 2021-2030 (USD Million) Figure 35: Cholesterol Testing Products Market, 2021-2030 (USD Million) 8.10 Cancer Marker Testing Products 8.10.1 Cancer Marker Testing Products Market, 2021-2030 (USD Million) Figure 36: Cancer Marker Testing Products Market, 2021-2030 (USD Million) 8.11 Urinalysis Testing Products 8.11.1 Urinalysis Testing Products Market, 2021-2030 (USD Million) Figure 37: Urinalysis Testing Products Market, 2021-2030 (USD Million) 8.12 Hematology Testing Products 8.12.1 Hematology Testing Products Market, 2021-2030 (USD Million) Figure 38: Hematology Testing Products Market, 2021-2030 (USD Million) 8.13 Drugs-of-abuse Testing Products 8.13.1 Drugs-of-abuse Testing Products Market, 2021-2030 (USD Million) Figure 39: Drugs-of-abuse Testing Products Market, 2021-2030 (USD Million) 8.14 Other POC Products 8.14.1 Other POC Products Market, 2021-2030 (USD Million) Figure 40: Other POC Products Market, 2021-2030 (USD Million) Chapter 9. Global Market: End-User Segment Analysis 9.1 Introduction 9.2 Sales Volume & Revenue Analysis (2021-2030) Table 10: Market, By End-User, 2021–2030 (USD Million) Figure 41: Market, By End-User, 2021–2030 (USD Million) Figure 42: Hospitals and Critical Care Centers Segment to Register Highest CAGR in Market during Forecast Period 9.3 Hospitals and Critical Care Centers 9.3.1 Hospitals and Critical Care Centers Market, 2021-2030 (USD Million) Figure 43: Hospitals and Critical Care Centers Market, 2021-2030 (USD Million) 9.4 Home Care 9.4.1 Home Care Market, 2021-2030 (USD Million) Figure 44: Home Care Market, 2021-2030 (USD Million) 9.5 Outpatient and Ambulatory Care Facilities 9.5.1 Outpatient and Ambulatory Care Facilities Market, 2021-2030 (USD Million) Figure 45: Outpatient and Ambulatory Care Facilities Market, 2021-2030 (USD Million) 9.6 Others 9.6.1 Others Market, 2021-2030 (USD Million) Figure 46: Others Market, 2021-2030 (USD Million) Chapter 10. Market: Mode of Purchase Segment Analysis 10.1 Introduction 10.2 Sales Volume & Revenue Analysis (2021-2030) Table 11 Market, By Mode of Purchase, 2021–2030 (USD Million) Figure 47 Market, By Mode of Purchase Figure 48 OTC Testing Products Segment to Register Highest CAGR in Market During Forecast Period 10.3 OTC Testing Products 10.3.1 OTC Testing Products Market, 2021-2030 (USD Million) Figure 49: OTC Testing Products Market, 2021-2030 (USD Million) 10.4 Prescription-based Testing Products 10.4.1 Prescription-based Testing Products Market, 2021-2030 (USD Million) Figure 50: Prescription-based Testing Products Market, 2021-2030 (USD Million) Chapter 11. Global Market: Platform Segment Analysis 11.1 Introduction 11.2 Sales Volume & Revenue Analysis (2021-2030) Table 12 Market, By Platform, 2021–2030 (USD Million) Figure 51 Market, By Platform Figure 52 Lateral Flow Assays Segment to Register Highest CAGR in Market During Forecast Period 11.3 Lateral Flow Assays 11.3.1 Lateral Flow Assays Market, 2021-2030 (USD Million) Figure 53: Lateral Flow Assays Market, 2021-2030 (USD Million) 11.4 Immunoassays 11.4.1 Immunoassays Market, 2021-2030 (USD Million) Figure 54: Immunoassays Market, 2021-2030 (USD Million) 11.4 Microfluidics 11.4.1 Microfluidics Market, 2021-2030 (USD Million) Figure 55: Microfluidics Market, 2021-2030 (USD Million) 11.4 Molecular Diagnostics 11.4.1 Molecular Diagnostics Market, 2021-2030 (USD Million) Figure 56: Molecular Diagnostics Market, 2021-2030 (USD Million) 11.4 Dipsticks 11.4.1 Dipsticks Market, 2021-2030 (USD Million) Figure 57: Dipsticks Market, 2021-2030 (USD Million) Chapter 12. Global Market: Regional Outlook 12.1 North America Figure 58: North America Market, By Revenue Forecast (2021-2030) 12.1.1 North America Market, by country, 2021-2030 (USD Million) Table 13: North America Market, by Country, 2021-2030 Figure 59: North America Market 12.1.2 North America Market, by Product, 2021-2030 (USD Million) Table14: North America Market, by Product, 2021-2030 (USD Million) Figure 60: North America Market, by Product, 2021-2030 (USD Million) 12.1.3 North America Market, by End-User, 2021-2030 (USD Million) Table 15: North America Market, by End-User, 2021-2030 (USD Million) Figure 61: North America Market, by End-User, 2021-2030 (USD Million) 12.1.4 U.S. 13.1.4.1 U.S. Market, by Product, 2021-2030 (USD Million) Figure 62: U.S. Market, by Product, 2021-2030 (USD Million) 12.1.4.2 U.S. Market, By End-User, 2021-2030 (USD Million) Figure 63: U.S. Market, By End-User, 2021-2030 (USD Million) 12.1.5 Canada 12.1.5.1 Canada Market, by Product, 2021-2030 (USD Million) Figure 64: Canada Market, by Product, 2021-2030 (USD Million) 12.1.5.2 Canada Market, by End-User, 2021-2030 (USD Million) Figure 65: Canada Market, by End-User, 2021-2030 (USD Million) Figure 66: Canada Market, by End-User, 2021-2030 (USD Million) Figure 67: Canada Market, by End-User, 2021-2030 (USD Million) 12.2 Europe Figure 68: Europe Market, By Revenue Forecast (2021-2030) 12.2.1 Europe Market, by country, 2021-2030 (USD Million) Table 16: Europe Market, by country, 2021-2030 (USD Million) Figure 69: Europe Market, by country, 2021-2030 (USD Million) 12.2.2 Europe Market, by Product, 2021-2030 (USD Million) Table 17: Europe Market, by Product, 2021-2030 (USD Million) Figure 70: Europe Market, by Product, 2021-2030 (USD Million) 12.2.3 Europe Market, By End-User, 2021-2030 (USD Million) Table 18: Europe Market, By End-User, 2021-2030 (USD Million) Figure 71: Europe Market, By End-User, 2021-2030 (USD Million) 12.2.4 U.K. 12.2.4.1 U.K. Market, by Product, 2021-2030 (USD Million) Figure 72: U.K. Market, by Product, 2021-2030 (USD Million) 12.2.4.2 U.K. Market, by End-User, 2021-2030 (USD Million) Figure 73: U.K. Market, by End-User, 2021-2030 (USD Million) 12.2.5 Germany 12.2.5.1 Germany Market, by Product, 2021-2030 (USD Million) Figure 74: Germany Market, by Product, 2021-2030 (USD Million) 12.2.5.2 Germany Market, By End-User, 2021-2030 (USD Million) Figure 75: Germany Market, By End-User, 2021-2030 (USD Million) 12.2.6 France 13.2.6.1 France Market, by Product, 2021-2030 (USD Million) Figure 76: France Market, by Product, 2021-2030 (USD Million) 12.2.6.2 France Market, By End-User, 2021-2030 (USD Million) Figure 77: France Market, by End-User, 2021-2030 (USD Million) 12.2.7 Rest of Europe 12.2.7.1 Rest of Europe Market, by Product, 2021-2030 (USD Million) Figure 78: Rest of Europe Market, by Product, 2021-2030 (USD Million) 12.2.7.2 Rest of Europe Market, by End-User, 2021-2030 (USD Million) Figure 79: Rest of Europe Market, by End-User, 2021-2030 (USD Million) 12.3 Asia Pacific Figure 80: Asia Pacific Market, By Revenue Forecast (2021-2030) 12.3.1 Asia Pacific Market, by country, 2021-2030 (USD Million) Table 29: Asia Pacific Market, by country, 2021-2030 (USD Million) Figure 81: Asia Pacific Market, by country, 2021-2030 (USD Million) 12.3.2 Asia Pacific Market, by Product, 2021-2030 (USD Million) Table 20: Asia Pacific Market, by Product, 2021-2030 (USD Million) Figure 82: Asia Pacific Market, by Product, 2021-2030 (USD Million) 12.3.3 Asia Pacific Market, By End-User, 2021-2030 (USD Million) Table 21: Asia Pacific Market, By End-User, 2021-2030 (USD Million) Figure 83: Asia Pacific Market, by End-User, 2021-2030 (USD Million) 12.3.4 China 10.3.4.1 China Market, by Product, 2021-2030 (USD Million) Figure 84: China Market, by Product, 2021-2030 (USD Million) 13.3.4.2 China Market, By End-User, 2021-2030 (USD Million) Figure 85: China Market, By End-User, 2021-2030 (USD Million) 12.3.5 India 12.3.5.1 India Market, by Product, 2021-2030 (USD Million) Figure 86: India Market, by Product, 2021-2030 (USD Million) 12.3.5.2 India Market, by End-User, 2021-2030 (USD Million) Figure 87: India Market, by End-User, 2021-2030 (USD Million) 12.3.6 Japan 12.3.6.1 Japan Market, By Product, 2021-2030 (USD Million) Figure 88: Japan Market, By Product, 2021-2030 (USD Million) 12.3.6.2 Japan Market, By End-User, 2021-2030 (USD Million) Figure 89: Japan Market, By End-User, 2021-2030 (USD Million) 12.3.7 South Korea 12.3.7.1 South Korea Market, by Product, 2021-2030 (USD Million) Figure 90: South Korea Market, by Product, 2021-2030 (USD Million) 12.3.7.2 South Korea Market, by End-User, 2021-2030 (USD Million) Figure 91: South Korea Market, by End-User, 2021-2030 (USD Million) 12.3.8 Rest of APAC 12.3.8.1 Rest of APAC Market, by Product, 2021-2030 (USD Million) Figure 92: Rest of APAC Market, by Product, 2021-2030 (USD Million) 12.3.8.2 Rest of APAC Market, by End-User, 2021-2030 (USD Million) Figure 93: Rest of APAC Market, by End-User, 2021-2030 (USD Million) 12.4 Latin America Figure 94: Latin America Market, By Revenue Forecast (2021-2030) 12.4.1 Latin America Market, by country, 2021-2030 (USD Million) Table 22: Latin America Market, by country, 2021-2030 (USD Million) Figure 95: Latin America Market, by country, 2021-2030 (USD Million) 12.4.2 Latin America Market, by Product, 2021-2030 (USD Million) Table 23: Latin America Market, by Product, 2021-2030 (USD Million) Figure 96: Latin America Market, by Product, 2021-2030 (USD Million) 12.4.3 Latin America Market, by End-User, 2021-2030 (USD Million) Table 24: Latin America Market, by End-User, 2021-2030 (USD Million) Figure 97: Latin America Market, by End-User, 2021-2030 (USD Million) 12.4.4 Brazil 12.4.4.1 Brazil Market, by Product, 2021-2030 (USD Million) Figure 98: Brazil Market, by Product, 2021-2030 (USD Million) 12.4.4.2 Brazil Market, by End-User, 2021-2030 (USD Million) Figure 99: Brazil Market, by End-User, 2021-2030 (USD Million) 12.4.5 Mexico 12.4.5.1 Mexico Market, by Product, 2021-2030 (USD Million) Figure 100: Mexico Market, by Product, 2021-2030 (USD Million) 12.4.5 2 Mexico Market, by End-User, 2021-2030 (USD Million) Figure 101: Mexico Market, by End-User, 2021-2030 (USD Million) 12.4.6 Rest of the Latin America 12.4.6.1 Rest of the Latin America Market, by Product, 2021-2030 (USD Million) Figure 102: Rest of the Latin America Market, by Product, 2021-2030 (USD Million) 12.4.6.2 Rest of the Latin America Market, by End-User, 2021-2030 (USD Million) Figure 103: Rest of the Latin America Market, by End-User, 2021-2030 (USD Million) 12.5 MEA Figure 104: MEA Market, By Revenue Forecast (2021-2030) 12.5.1 MEA Market, by Product, 2021-2030 (USD Million) Figure 105: MEA Market, by Product, 2021-2030 (USD Million) 12.5.2 MEA Market, by End-User, 2021-2030 (USD Million) Figure 106: MEA Market, by End-User, 2021-2030 (USD Million) Chapter 13. Competitive Landscape 13.1 Roche Diagnostics. 13.1.1 Company overview 13.1.2 Financial performance 13.1.3 Product Portfolio Analysis 13.1.4 Business Strategy & Recent Development 13.2 Siemens Healthineers. 13.2 .1 Company overview 13.2 .2 Financial performance 13.2 .3 Product Portfolio Analysis 13.2 .4 Business Strategy & Recent Development 13.3 Abbott Laboratories. 13.3.1 Company overview 13.3.2 Financial performance 13.3.3 Product Portfolio Analysis 13.3.4 Business Strategy & Recent Development 13.4 Danaher Corporation. 13.4.1 Company overview 13.4.2 Financial performance 13.4.3 Product Portfolio Analysis 13.4.4 Business Strategy & Recent Development 13.5 Becton Dickinson and Company. 13.5.1 Company overview 13.5.2 Financial performance 13.5.3 Product Portfolio Analysis 13.5.4 Business Strategy & Recent Development 13.6 Chembio Diagnostics. 13.6.1 Company overview 13.6.2 Financial performance 13.6.3 Product Portfolio Analysis 13.6.4 Business Strategy & Recent Development 13.7 Quidel Diagnostics. 13.7.1 Company overview 13.7.2 Financial performance 13.7.3 Product Portfolio Analysis 13.7.4 Business Strategy & Recent Development 13.8 EKF Diagnostics. 13.8.1 Company overview 13.8.2 Financial performance 13.8.3 Product Portfolio Analysis 13.8.4 Business Strategy & Recent Development 13.9 Trinity Biotech. 13.9.1 Company overview 13.9.2 Financial performance 13.9.3 Product Portfolio Analysis 13.9.4 Business Strategy & Recent Development 13.10 Fluxergy. 13.10.1 Company overview 13.10.2 Financial performance 13.10.3 Product Portfolio Analysis 13.10.4 Business Strategy & Recent Development